Intellia Therapeutics to Present at September Healthcare Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/23/2026

1. SPY
2. KBH
3. PATH
4. USO
5. AZO

6. ORCL
7. QQQ
8. RCL
9. ONON
10. PLTR

Get Alerts NTLA Hot Sheet

Price: $12.33 -2.84%

Overall Analyst Rating:
SELL (= Flat)

EPS Growth %: +13.0%

Join SI Premium – FREE

CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following virtual healthcare investor conferences in September:

Thursday, September 9, 2021Wells Fargo Healthcare ConferenceTime: 10:40 am ET

Monday, September 13, 2021H.C. Wainwright 23rd Annual Global Investment ConferenceTime: 7:00 am ET

A live webcast of Intellia’s presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each presentation.

About Intellia TherapeuticsIntellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:Ian KarpSenior Vice President, Investor Relations and Corporate Communications+1-857-449-4175[email protected]

Lina LiDirector, Investor Relations+1-857-706-1612[email protected]